Strand Life Sciences secures AI patent for blood test to detect cancer early
In a significant step towards advancing early cancer detection in India, Strand Life Sciences, a subsidiary of Reliance Industries Limited, has been granted an Indian patent for an integrated platform that uses artificial intelligence (AI) and cell-free DNA (cfDNA) analysis to detect cancer from a simple blood sample.
The patented technology combines high-quality genome sequencing, stringent quality control, methylation and fragmentomic analysis, and machine learning algorithms to identify early cancer-related changes in DNA circulating in the bloodstream. It can also predict the tissue of origin of the cancer, enabling doctors to investigate the affected organ at an earlier stage.
A Blood Test That Could Change Cancer Screening
One of the key innovations covered by the patent is its ab...








